- Home
- WELL vs BMY Comparison
WELL vs BMY Comparison
Compare WELL & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WELL | BMY |
|---|---|---|
| Founded | 1970 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.1B | 110.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WELL | BMY |
|---|---|---|
| Price | $185.91 | $56.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $208.90 | $57.50 |
| AVG Volume (30 Days) | 3.7M | ★ 15.5M |
| Earning Date | 02-10-2026 | 02-05-2026 |
| Dividend Yield | 1.59% | ★ 4.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.46 | ★ 2.97 |
| Revenue | $9,907,853,000.00 | ★ $48,034,000,000.00 |
| Revenue This Year | $31.06 | $0.27 |
| Revenue Next Year | $20.18 | N/A |
| P/E Ratio | $127.24 | ★ $19.09 |
| Revenue Growth | ★ 32.28 | 1.26 |
| 52 Week Low | $123.11 | $42.52 |
| 52 Week High | $209.05 | $63.33 |
Technical Indicators
Market Signals| Indicator | WELL | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 41.00 | 70.91 |
| Support Level | $181.91 | $52.06 |
| Resistance Level | $187.03 | $55.04 |
| Average True Range (ATR) | 2.96 | 0.93 |
| MACD | -0.39 | -0.10 |
| Stochastic Oscillator | 39.75 | 94.66 |
Price Performance
Historical ComparisonAbout WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,391 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.